Clinical Trials Sponsored by Vifor Pharma

Total 8315 results

LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris

Psoriasis Vulgaris

Canada
UCB Pharma

Completed

A Study of Brivaracetam in Subjects With Partial Onset Seizures

Epilepsy, Focal

France, Poland, United Kingdom, Belgium, Germany, Spain, Czech Republic, Finland, Netherlands
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Plus Betamethasone Gel in the Treatment of Scalp Psoriasis

Psoriasis of Scalp

Canada, Denmark, France, Norway, Portugal, Spain, Sweden, United Kingdom
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris

Psoriasis Vulgaris

Belgium, Canada, France, Germany, Netherlands, Spain, United Kingdom
LEO Pharma

Completed

Efficacy of Calcipotriol Plus Betamethasone Gel Versus Calcipotriol Scalp Solution in Scalp Psoriasis

Psoriasis of Scalp

France, Canada, Belgium, Denmark, Sweden
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Psoriasis Vulgaris

Psoriasis Vulgaris

Ireland, Germany, United Kingdom, Canada, Sweden
LEO Pharma

Completed

Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis

Psoriasis

United States
UCB Pharma

Completed

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin (PAL)

Allergic Rhinitis | Chronic Urticaria

United States
Innate Pharma

Completed

Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Germany
UCB Pharma

Completed

Observational Study in Infants Who Are Prescribed Treatment With Keppra® (Levetiracetam) Oral Solution

Epilepsy

France, Germany, Greece, Italy, Poland, Spain, United Kingdom
UCB Pharma

Completed

Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder

Generalized Anxiety Disorder | Panic Disorder

United States
UCB Pharma

Completed

Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch

Parkinson's Disease

United States, Chile, Mexico, India, Peru
UCB Pharma

Terminated

Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease

Parkinson's Disease

Spain, South Africa, New Zealand, Hungary, United States, Germany, Italy, Australia, Finland, United Kingdom, Poland
UCB Pharma

Terminated

Alprostadil in Maculopathy Study (AIMS)

Macular Degeneration

Germany
UCB Pharma

Completed

Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in Healthy Korean Subjects

Parkinson's Disease

Korea, Republic of
UCB Pharma

Completed

A Trial to Investigate Safety and Efficacy of SPM927 in Painful Diabetic Neuropathy

Painful Diabetic Neuropathy
UCB Pharma

Completed

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease

Early Stage Parkinson's Disease

Poland, United Kingdom, Germany, Spain, Switzerland, Belgium, South Africa, New Zealand, Czech Republic, Austria, Hungary, Australia, Italy, Israel, Sweden, Norway, Croatia, Netherlands, Finland, France
UCB Pharma

Completed

An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease

Idiopathic Parkinson's Disease

United States, Germany, Spain, Austria, Israel, Italy, South Africa, United Kingdom
UCB Pharma

Completed

A Trial to Compare the Efficacy of Rotigotine Transdermal Patch to That of Ropinirole on Early Morning Motor Impairment and Sleep Disorders in Subjects With Early-Stage, Idiopathic Parkinson's Disease

Parkinson's Disease

Germany
UCB Pharma

Completed

An Extension Trial to Investigate Long-Term Treatment With Transdermal Rotigotine in Idiopathic Restless Legs Syndrome

Restless Legs Syndrome

United States
UCB Pharma

Completed

An Open-Label Follow-on Trial to Assess the Long-Term Safety and Efficacy of Oral SPM 927 in Subjects With Postherpetic Neuralgia (PHN)

Postherpetic Neuralgia

Germany
UCB Pharma

Completed

A Trial to Assess the Efficacy and Safety of SPM 927 (Lacosamide) in Subjects With Painful Distal Diabetic Neuropathy

Diabetic Neuropathy

Germany
UCB Pharma

Completed

Conversion to Monotherapy Study With Keppra XR for Partial Seizures

Epilepsy

Poland, United States, Mexico, Russian Federation
UCB Pharma

Completed

Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

Rheumatoid Arthritis

United States, Belgium, United Kingdom
UCB Pharma

Terminated

Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction (ROADMAP)

Advanced Parkinson's Disease

United States
Evoke Pharma

Completed

Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Patients With Gastroparesis

Diabetes Mellitus | Diabetes | Gastroparesis | Delayed Gastric Emptying | Diabetic Gastroparesis

United States
Edmond Pharma

Unknown

The Efficacy and Safety of Erdosteine in Chronic Obstructive Pulmonary Disease (COPD) (RESTORE)

Chronic Obstructive Pulmonary Disease (COPD)

Belgium, Bulgaria, Czech Republic, Denmark, France, Italy, Poland, Romania, Slovakia, United Kingdom
AM-Pharma

Withdrawn

A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Bacteremia Due to S. Epidermidis (LIST)

Bacteremia | Staphylococcal Infections

Netherlands
UCB Pharma

Completed

Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA) (MARVELOUS)

Rheumatoid Arthritis

Denmark, Netherlands, Poland, Sweden
LEO Pharma

Completed

Topical Treatment of Scalp Psoriasis With the Fixed Combination of Calcipotriol and Betamethason (Xamiol® Gel)

Scalp Psoriasis

Germany
UCB Pharma

Completed

Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

Japan
UCB Pharma

Completed

POPULAR (Preference Of Patient Using Levocetirizine in Allergic Rhinitis)

Seasonal Allergic Rhinitis
UCB Pharma

Completed

Compare the Efficacy of Levocetirizine to Montelukast in Reducing Symptoms of SAR in Sensitive Subjects Exposed to Ragweed Pollen

Rhinitis, Allergic, Seasonal

Canada
UCB Pharma

Completed

Efficacy and Safety of Levocetirizine for Treatment of Recurrent Cough Associated With Other Allergic Symptoms in Children

Cough
UCB Pharma

Completed

Double-blind, Placebo-controlled Study of Levetiracetam in Adults With POS

Epilepsy, Partial
UCB Pharma

Completed

Open Label Safety and Efficacy Study of Levetiracetam in Korean Patients With Epilepsy

Epilepsy, Partial
UCB Pharma

Completed

A 16 Week Study Evaluating Levetiracetam in the Treatment of Post Herpetic Neuralgia (PHN)

Neuralgia, Postherpetic
LEO Pharma

Completed

The Impact of Renal Impairment on the Pharmacokinetic and Pharmacodynamic of LEO 27847

Renal Impairment

Canada
LEO Pharma

Completed

LEO 22811 - Single Dose Bioavailability Study of Tablet Versus Oral Solution in Healthy Subjects

Healthy

United Kingdom
LEO Pharma

Completed

Assessment of the Phototoxic Potential of LEO 29102 Cream

Atopic Dermatitis

France
LEO Pharma

Completed

A Safety, Tolerability and Pharmacokinetic Study of LEO 29102 in Subjects With Atopic Dermatitis

Atopic Dermatitis

Netherlands
Clavis Pharma

Completed

A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies

AML | Hematologic Malignancies

United States, United Kingdom, France, Germany, Italy, Norway
UCB Pharma

Completed

Levetiracetam as add-on Treatment of Myoclonic Jerks in Adolescents + Adults

Generalized Convulsive Epilepsy
Clavis Pharma

Completed

A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer

Ovarian Cancer

Belgium, Italy
Clavis Pharma

Completed

Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma

Malignant Melanoma

United States, Sweden, Norway
UCB Pharma

Completed

Efficacy and Safety of CDP870 and Methotrexate Compared to Methotrexate Alone in Subjects With Rheumatoid Arthritis

Arthritis, Rheumatoid
Clavis Pharma

Completed

Elacytarabine Mass Balance Study in Healthy Volunteers

Not Applicable as This is a Mass Balance/Pharmacokinetic Study Performed in Healthy Subjects

United Kingdom
Advanz Pharma

Withdrawn

A Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation (AF) (MK-6621-055)

Atrial Fibrillation
UCB Pharma

Completed

Belgian Drug-utilization Study to Evaluate the Use of VIMPAT® as Adjunctive Treatment of Partial Onset Seizures in Subjects Aged 16 and Older

Seizures

Belgium
Kiadis Pharma

Completed

Dose-ranging Study of a Single Administration of T-cell Add-back Depleted of Host Alloreactive Cells in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

Hematologic Diseases | Hematologic Malignancies

Canada

3

Subscribe